Update on Treatments for Premature Ejaculation

W. J. G. Hellstrom


Int J Clin Pract. 2011;65(1):16-26. 

In This Article

Concluding Statements

With the publication of the 2008 International Society of Sexual Medicine definition of PE, and thus a standardised, reliable method for correctly identifying men with PE for clinical trial evaluation, further progress in the evaluation and diagnosis of PE is anticipated. While serotonergic antidepressants are commonly used in daily dosing protocols, there are recognised limitations. The impetus in current PE drug development is towards on-demand therapy, with both dapoxetine and PSD502 in advanced stages of clinical development. These drugs have demonstrated safety, objective improvement in IELT and subjective improvement in patient and partner satisfaction. While the known systemic side effects of antidepressants are reduced by the on-demand dosing regimen of dapoxetine, PSD502 administration is associated with minimal systemic side effects. Tramadol is another drug that shows promise, but the data available from small trials need to be corroborated by ongoing phase III studies; in addition, long-term studies are warranted to investigate the risk of opioid addiction. Coupled with efficient diagnosis, emerging treatments for PE should significantly improve the quality of life for men who suffer from PE.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: